Laura P Stabile1, Mariya Farooqui2, Beatriz Kanterewicz3, Shira Abberbock3, Brenda F Kurland4, Brenda Diergaarde5, Jill M Siegfried6. 1. Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania; UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania. Electronic address: stabilela@upmc.edu. 2. Department of Pharmacology, University of Minnesota, Minneapolis, Minnesota. 3. UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania. 4. Department of Biostatistics, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania. 5. UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania; Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pennsylvania. 6. Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Pharmacology, University of Minnesota, Minneapolis, Minnesota.
Abstract
INTRODUCTION: A hormonal role in NSCLC development is well documented. We previously showed that the aromatase inhibitor (AI) anastrozole decreased development of tobacco carcinogen-induced lung tumors in a murine lung cancer prevention model and that aromatase and estrogen receptor were expressed in pulmonary inflammatory cells. METHODS: We utilized a tobacco carcinogen-induced lung tumor mouse model by treatment with 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone (NNK), to determine whether an AI combined with nonsteroidal anti-inflammatory drugs results in greater lung tumor prevention effects compared to single-agent treatment. RESULTS: Combination of anastrozole (0.1 mg/kg/d) with aspirin (25 mg/kg/d) after NNK exposure resulted in significantly fewer and smaller lung tumors than did single-agent treatments and was accompanied by maximum decreases in circulating β-estradiol (E2) and interleukin-6, tumor-infiltrating macrophages, and tumoral Ki67, phospho-mitogen-activated protein kinase, phospho-signal transducer and activator of transcription 3, and interleukin-17A expression. Preneoplasia arising after combination treatment showed the lowest Sox-2 expression, suggesting an inhibitory effect on proliferative capacity in the airways by blocking both E2 and inflammation. Anastrozole combined with ibuprofen instead of aspirin also showed enhanced antitumor effects. Moreover, male mice treated with NNK that received E2 in their drinking water showed greater levels of pulmonary macrophages and inflammatory markers than did the control, confirming an E2 effect on inflammation in the microenvironment. CONCLUSIONS: Our results suggest a benefit to joint targeting of the estrogen and inflammatory pathways for NSCLC prevention. Combining AIs with nonsteroidal anti-inflammatory drugs reduces circulating E2, proinflammatory cytokines, and macrophage recruitment in the lung microenvironment after tobacco exposure. This strategy could be particularly effective in women who have underlying pulmonary inflammatory diseases.
INTRODUCTION: A hormonal role in NSCLC development is well documented. We previously showed that the aromatase inhibitor (AI) anastrozole decreased development of tobacco carcinogen-induced lung tumors in a murinelung cancer prevention model and that aromatase and estrogen receptor were expressed in pulmonary inflammatory cells. METHODS: We utilized a tobacco carcinogen-induced lung tumormouse model by treatment with 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone (NNK), to determine whether an AI combined with nonsteroidal anti-inflammatory drugs results in greater lung tumor prevention effects compared to single-agent treatment. RESULTS: Combination of anastrozole (0.1 mg/kg/d) with aspirin (25 mg/kg/d) after NNK exposure resulted in significantly fewer and smaller lung tumors than did single-agent treatments and was accompanied by maximum decreases in circulating β-estradiol (E2) and interleukin-6, tumor-infiltrating macrophages, and tumoralKi67, phospho-mitogen-activated protein kinase, phospho-signal transducer and activator of transcription 3, and interleukin-17A expression. Preneoplasia arising after combination treatment showed the lowest Sox-2 expression, suggesting an inhibitory effect on proliferative capacity in the airways by blocking both E2 and inflammation. Anastrozole combined with ibuprofen instead of aspirin also showed enhanced antitumor effects. Moreover, male mice treated with NNK that received E2 in their drinking water showed greater levels of pulmonary macrophages and inflammatory markers than did the control, confirming an E2 effect on inflammation in the microenvironment. CONCLUSIONS: Our results suggest a benefit to joint targeting of the estrogen and inflammatory pathways for NSCLC prevention. Combining AIs with nonsteroidal anti-inflammatory drugs reduces circulating E2, proinflammatory cytokines, and macrophage recruitment in the lung microenvironment after tobacco exposure. This strategy could be particularly effective in women who have underlying pulmonary inflammatory diseases.
Authors: Paul E Goss; James N Ingle; José E Alés-Martínez; Angela M Cheung; Rowan T Chlebowski; Jean Wactawski-Wende; Anne McTiernan; John Robbins; Karen C Johnson; Lisa W Martin; Eric Winquist; Gloria E Sarto; Judy E Garber; Carol J Fabian; Pascal Pujol; Elizabeth Maunsell; Patricia Farmer; Karen A Gelmon; Dongsheng Tu; Harriet Richardson Journal: N Engl J Med Date: 2011-06-04 Impact factor: 91.245
Authors: Joshua E Muscat; Shu-Quan Chen; John P Richie; Nasser K Altorki; Marc Citron; Sara Olson; Alfred I Neugut; Steven D Stellman Journal: Cancer Date: 2003-04-01 Impact factor: 6.860
Authors: Kotha Subbaramaiah; Patrick G Morris; Xi Kathy Zhou; Monica Morrow; Baoheng Du; Dilip Giri; Levy Kopelovich; Clifford A Hudis; Andrew J Dannenberg Journal: Cancer Discov Date: 2012-01-27 Impact factor: 39.397
Authors: Ran Ma; Govindasamy-Muralidharan Karthik; John Lövrot; Felix Haglund; Gustaf Rosin; Anne Katchy; Xiaonan Zhang; Lisa Viberg; Jan Frisell; Cecilia Williams; Stig Linder; Irma Fredriksson; Johan Hartman Journal: J Natl Cancer Inst Date: 2017-03-01 Impact factor: 13.506
Authors: Barbara Nuvoli; Barbara Antoniani; Roberta Libener; Antonio Maconi; Andrea Sacconi; Mariantonia Carosi; Rossella Galati Journal: J Exp Clin Cancer Res Date: 2021-08-17
Authors: Daria S Chulpanova; Kristina V Kitaeva; Catrin S Rutland; Albert A Rizvanov; Valeriya V Solovyeva Journal: Int J Mol Sci Date: 2020-06-09 Impact factor: 5.923